CN1208635A - Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease - Google Patents
Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease Download PDFInfo
- Publication number
- CN1208635A CN1208635A CN 97116364 CN97116364A CN1208635A CN 1208635 A CN1208635 A CN 1208635A CN 97116364 CN97116364 CN 97116364 CN 97116364 A CN97116364 A CN 97116364A CN 1208635 A CN1208635 A CN 1208635A
- Authority
- CN
- China
- Prior art keywords
- tea pigment
- treatment
- application
- oral
- oral submucosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a new medicinal application of tea pigment, i. e. the tea pigment can be used for curing oral submucosa fibrous pathalogic change.
Description
The present invention relates to the new medicine use of tea pigment, be specifically related to the application of tea pigment in preparation treatment oral submucosa fibrosis's medicine, belong to the field of Chinese medicines.
Tea pigment is the natural plant pigment that extracts from Folium Camelliae sinensis, is a kind of active pigment complex that catechin forms through peroxidating in the tea polyphenols.Tea pigment is made up of theaflavin, thearubigins and abrownin.For the existing bibliographical information of the research of tea pigment.CN1074618A discloses tea pigment and production method thereof.This production process is, Folium Camelliae sinensis is through decocting extracting juice, and alkalization concentrates, and acidify adds alcohol reflux, and alcohol reflux liquid alkalizes and obtains tea pigment crystallization product, through vacuum drying, promptly obtains this tea pigment.Theaflavin, thearubigins and abrownin three have constant ratio in the tea pigment that makes with this method, can be used as medicinal.Medical value report for tea pigment may be summarized to be reduction blood viscosity, blood fat reducing, cholesterol reducing, prevention and treatment cardiovascular disease.But up to the present, the relevant tea pigment of Shang Weijian is used for the treatment of oral submucosa fibrosis's report.
A kind of new pharmaceutical applications that the purpose of this invention is to provide tea pigment, promptly tea pigment is in the application of preparation treatment oral submucosa fibrosis's medicine.
(Oral Submucous fibrosis is a kind of chronic invisible, disease of being difficult to cure osf) to the oral submucosa fibrosis, and its pathogeny is very unclear, but discovery is relevant with factors such as microcirculation and hemorheologys.Zoopery and clinical observation confirm that tea pigment has therapeutical effect to the oral submucosa fibrosis.
The extracting method of tea pigment of the present invention can extract according to known extraction process, preferably the tea pigment that extracts according to following method:
(1), with Folium Camelliae sinensis by 1: after 15-30 multiple proportions example added water, through once or the decoction extracting juice once, fried liquid is used in the aqueous solution can produce OH
-Ionic chemical compound alkalizes, and regulates PH8-10, at the 1/4-1/10 that heats concentrated this alkaline solution to the original volume amount down less than 70 ℃, gets concentrated solution then; (2) concentrated solution transfers to PH3-6 with acid, and acidifying solution adds ethanol 1-10 volume doubly to be measured, and backflow 0.5-2 hour, gets alcohol reflux liquid; (3) alcohol reflux liquid is used in aqueous solution and can produces OH
-Ionic chemical compound is regulated PH7-10, and post precipitation filters, and gets the tea pigment crystallization, and tea pigment crystallization vacuum drying promptly gets the tea pigment product.
Tea pigment of the present invention is a kind of active constituents of medicine, preparation process according to routine, can be main active constituent with tea pigment, add excipient substances such as conventional excipient, flavoring agent, disintegrating agent, antiseptic, lubricant, wetting agent, binding agent, solvent, thickening agent, solubilizing agent, make any dosage form that is suitable for using clinically, as tablet, capsule, granule, oral liquid, injection etc.
Because the present invention discloses tea pigment treatment oral submucosa fibrosis's pharmacologic action first; therefore; tea pigment cooperated separately or with other active constituents or adjuvant make medicament,, all belong to protection scope of the present invention so long as this medicament is used for the treatment of the oral submucosa fibrosis.
Tea pigment of the present invention all has treatment oral submucosa fibrosis's effect when making any dosage form.Any medicament; if contain tea pigment in its component or only prepare patent medicine with the tea pigment single component; on signs such as its packing or description or on other any propaganda materials,, then fall within protection scope of the present invention as long as indicate or prompting has treatment oral submucosa fibrosis's effect.
Tea pigment of the present invention is the natural plants Folium Camelliae sinensis that derives from medicine-food two-purpose.Therefore, also tea pigment can be made health food or health care medicine.Health food or health care medicine with tea pigment is made have the effect for the treatment of the oral submucosa fibrosis if indicate or point out on signs such as its packing or description, also fall within protection scope of the present invention.
Embodiment 1
Prescription
Tea pigment 125 grams
Medical starch 875 grams
Above-mentioned component is gone into blender, and fully stirring and evenly mixing is encapsulated with capsule machine, and every filling 1 gram makes 1000 of tea pigment capsules, and every capsules contains 125 milligrams of tea pigments.
Embodiment 2
Tea pigment 250 grams
2000 milliliters of distilled water
Stevioside 1 gram
Tea pigment is dissolved in the distilled water, and fully mixing adds stevioside, and stirring and evenly mixing is once more packed in the vial with can packing machine, and every bottled 10 milliliters, sterilization makes the tea pigment oral liquid.
Experimental example: tea pigment treatment oral submucosa fibrosis's clinical observation
1, data and method
1.1 object of study: matched group is my outpatient of institute 22 examples of in January, 1996-August, 18 of male, 4 of women, in age 23-53 year, 38.2 years old mean age, seminar is in August, 1996-97 year January 17 of my outpatients of institute, 13 of male, 4 of women, age 20-58 year, 40.4 years old mean age.All be diagnosed as osf on two groups of patients clinicals and the pathology, clinical and pathological diagnosis standard is all carried out the perquisition personal history according to Pindborg to epidemiology and the pathological diagnostic criteria of OSF, understand smoking, drink, chew custom such as Semen Arecae, and get rid of relevant other disease, do not do treatment in the recent period.
1.2 medication: matched group gives oral VitBco2#, day 3 times, Vit AD2# day 2 times, VitE100mg, day 1 time, 30 days courses of treatment.Seminar adds tea pigment on this basis.Tea pigment capsule is by the development of the green pharmaceutical Co. Ltd in Chinese-foreign joint Jiangxi, every 125mg, 250mg/ time, every day 2 times, totally 30 days.Before the treatment, require two groups of patients Semen Arecae of not ruminating, eat or do not eat maror less, complete mouthful scaling is respectively done 20 times sooner or later and is opened the motions of remaining silent.
1.3 observation index
1.3.1 seminar's treatment previous crops Determination of Blood Rheology, diagnosis is divided into 4 groups according to the blood samples of patients rheology, and normally the person is the A group, and blood high viscosity syndrome I, II, III level are respectively B, C, D group, observes treatment front and back mouth opening and improves situation.
1.3.2 observe before two groups of patient and back 30 days oral mucosa thorns of treatment Severe Pain, stiff sense, blister and the mouth opening situation of change repeatedly.
1.3.3 criterion of therapeutical effect
Produce effects: opening degree (surveying distance between thirty incisxal edge) improves more than the 10mm, and recurrent stomatitis, ulcer disappear, oral mucosa thorn Severe Pain, stiff sense disappearance or obvious the improvement.
Effectively: opening degree is increased in the 10mm; Oral mucosa thorn Severe Pain, stiff sense are partly alleviated; Recurrent stomatitis, ulcer recurrence gap phase prolong; More than having binomial to exist is effectively.
Invalid: original pathological changes symptom and sign does not have change, even worsens.
2, result
12 of the 17 philtrum hemorheology persons of changing of seminar account for 70.6%, treat the increase that back 7 patient's mouth openings have 3-15mm, on average increase 7.9mm, account for 58.3%.And behind 5 patient treatments of A group only 1 mouth opening increased 2mm slightly.Seminar's hemorheology changes and mouth opening improvement situation sees Table 1.
After the treatment of control group, thorn Severe Pain, stiff sense are alleviated to some extent, effective percentage 13.6%, but blister repeatedly, mouth opening does not have improvement.Seminar's symptom is then improved early and significantly, and mouth opening obviously increases, total effective rate 58.8%.Two groups there was a significant difference (u=3.229, p＜0.01).See Table 2, table 3.
Table 1 seminar hemorheology changes with mouth opening and improves situation
| The A group | The B group | The C group | The D group | |
| Number treatment back mouth opening improves the number mouth opening before the treatment on average increases (mm) | ????5 ????1 ????2 | ????3 ????1 ????7 | ????6 ????3 ????7.7 | ????3 ????3 ????8.3 |
Table 2 liang group clinical symptoms, sign are improved situation
| The thorn Severe Pain | Stiff sense | Blister repeatedly | Mouth opening | |||||
| The example number | The improvement rate | The example number | The improvement rate | The example number | The improvement rate | The example number | The improvement rate | |
| Matched group seminar | ???22 ???17 | ???45.5％ ???64.7％ | ???8 ???5 | ??37.5％ ??80％ | ???6 ???6 | ????0 ??33.3％ | ??22 ??17 | ????0 ??41.7％ |
Table 3 liang group clinical observation on the therapeutic effect contrast
| Produce effects | Effectively | Invalid | ||||
| Case load | ????％ | Case load | ????％ | Case load | ????％ | |
| Matched group seminar | ????0 ????2 | ????0 ??11.8％ | ????3 ????8 | ?13.6％ ?47.1％ | ????19 ????7 | ??86.4％ ??41.0％ |
3, discuss
3.1 describe OSF first from SCHWARTZ, its pathogeny and treatment are disputable always, it belongs to precancerous condition, is caused by multifactor, and is common relevant with the Semen Arecae stimulation.The domestic and international at present treatment to this disease mainly is Drug therapy and operative treatment.Drug therapy often gives oral VitBco, VitA.E, peripheral vasodilator example hydrochloric acid buphenine; Local injection hyaluronidase, dexamethasone can obtain certain curative effect, but all not really desirable.The operative treatment short-term effect is good, but at a specified future date because of operation can cause new cicatrization, causes the limitation of mouth opening recurrence.Thereby seek a comparatively ideal Therapeutic Method and be necessary.
3.2 microcirculation disturbance appears in the mechanism OSF patient oral cavity partial of tea pigment treatment OSF, serum IgA, IgG, IgM level increase, and the Circulating Immune Complexes in Sera level thereby might cause that hemorheology changes between oral cancer and normal person.We have all made Determination of Blood Rheology before to seminar's patient treatment, and blood high viscosity syndrome I level has 3 people, and the II level has 6 people, and the III level has 3 people, accounts for total number of persons 70.6%, confirms that also there is high viscosity in this class patient's blood.
The local fibrosis of osf patient's ischemia and secondary, cross developing of keratinization, malnutrition (VitB, potein deficiency, iron deficiency anemia) aggravation osf, there is viscosity of blood in addition, this has just more increased the weight of ischemia and malnutrition, impel the more serious of OSF pathological changes, form a kind of vicious cycle.And tea pigment clinical verification can reduce the blood high viscosity and high coagulant state, and microcirculation improvement is alleviated ischemia, and the supply of guarantee tissue blood and oxygen has additional nutrients and medicine reaches damaged tissues; And serum superoxide dismutase (SOD) vigor that significantly raises, remove free radical, the protection cell is undermined.After this group treatment, two patients (high blood viscosity II ° III ° each) have done the hemorheology check, and the result is normal, and this two patient's oral mucosas burn feeling, stiff sense, disappearances of blistering, mouth opening more than 38mm (before treating≤30mm)
Claims (2)
1, the application of tea pigment in preparation treatment oral submucosa fibrosis's medicine.
2, the application of tea pigment in preparation treatment oral submucosa fibrosis's health product.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116364A CN1064254C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease |
| PCT/CN1998/000167 WO1999008674A1 (en) | 1997-08-18 | 1998-08-18 | New uses of tea pigment |
| AU87973/98A AU8797398A (en) | 1997-08-18 | 1998-08-18 | New uses of tea pigment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97116364A CN1064254C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1208635A true CN1208635A (en) | 1999-02-24 |
| CN1064254C CN1064254C (en) | 2001-04-11 |
Family
ID=5173798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97116364A Expired - Fee Related CN1064254C (en) | 1997-08-18 | 1997-08-18 | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1064254C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614494A (en) * | 2012-04-26 | 2012-08-01 | 中南大学 | Oral submucous fibrosis rat model construction method |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1035660C (en) * | 1993-01-01 | 1997-08-20 | 江西省绿色工业(集团)公司 | Tea pigment and preparing process thereof |
-
1997
- 1997-08-18 CN CN97116364A patent/CN1064254C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614494A (en) * | 2012-04-26 | 2012-08-01 | 中南大学 | Oral submucous fibrosis rat model construction method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1064254C (en) | 2001-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100534474C (en) | Medicine composition for enhancing immunity, and its preparation method and use | |
| US11439681B2 (en) | Traditional Chinese medicine composition for treating type 2 diabetes | |
| CA2304596A1 (en) | A medicament for treating recurrent ulcer of mouth and behcet's syndrome | |
| CN101596249B (en) | Chinese medicinal composition and Chinese medicament for treating diarrhea and preparation method thereof | |
| CN102441070B (en) | Composition for alleviating eye fatigue | |
| CN109223637A (en) | Subprostrate sophora herbal mixture toothpaste and preparation method | |
| CN104042720A (en) | Traditional Chinese medicine for preventing and treating diabetes with depression and application of traditional Chinese medicine | |
| CN104083747B (en) | A kind of pharmaceutical composition for treating chronic gastritis and preparation method and purposes | |
| CN1064254C (en) | Application of theaflavine for preparing medicine for treating oral submucosa fibrous disease | |
| CN107501435A (en) | The extracting method of pachymaran and its application | |
| CN105148150A (en) | Healthcare tea and making method thereof | |
| CN1163228C (en) | Application of tea polyphenol and its oxide in treating muscular disease | |
| CN1065756C (en) | Application of theachrome in preparing medicine for prostatauxe | |
| CN108704036A (en) | A kind of Chinese traditional compound medicine and preparation method thereof for treating gout | |
| CN101897726A (en) | Traditional Chinese medicinal powder for treating oral ulcer | |
| CN1065758C (en) | Application of tea pigments in preparation of medicine for goiter | |
| CN106581468A (en) | Preparation method of traditional Chinese medicine capable of treating gastric ulcer | |
| CN107865953B (en) | Traditional Chinese medicine compound preparation for treating salivation and nocturia increase as well as preparation method and application thereof | |
| CN1078472C (en) | Application of theachrome in preparing medicine for plateau erythrocytosis | |
| CN1057007C (en) | Application of theachrome in preparing medicine for pulmonitis | |
| WO2023274151A1 (en) | Composition wtih uric acid reducing effect and use thereof | |
| CN1057005C (en) | Application of theaflavine for preparing medicine for treating leukopenia disease | |
| CN1066339C (en) | Application of theaflavine for prepn. of medicine for treating deafness | |
| CN1057008C (en) | Application of theachrome in preparing medicine for viral myocarditis | |
| RU2139071C1 (en) | Agent for treatment of patients with chronic hepatitis of noninfectious etiology complicated by chronic pancreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |